These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 18444843)
1. Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. De Wals P; Deceuninck G; Boucher RM; Ouakki M Clin Infect Dis; 2008 Apr; 46(8):e75-7. PubMed ID: 18444843 [TBL] [Abstract][Full Text] [Related]
2. Epidemiology of Guillain-Barré syndrome in the province of Quebec. Deceuninck G; Boucher RM; De Wals P; Ouakki M Can J Neurol Sci; 2008 Sep; 35(4):472-5. PubMed ID: 18973064 [TBL] [Abstract][Full Text] [Related]
3. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(41):1120-4. PubMed ID: 17060898 [TBL] [Abstract][Full Text] [Related]
4. Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions. De Wals P; Deceuninck G; Ouakki M; Boulianne N; De Serres G; Danzig L Vaccine; 2009 May; 27(24):3223-7. PubMed ID: 19446195 [TBL] [Abstract][Full Text] [Related]
5. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. De Wals P; Deceuninck G; Toth E; Boulianne N; Brunet D; Boucher RM; Landry M; De Serres G JAMA; 2012 Jul; 308(2):175-81. PubMed ID: 22782419 [TBL] [Abstract][Full Text] [Related]
6. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2006 Apr; 55(13):364-6. PubMed ID: 16601664 [TBL] [Abstract][Full Text] [Related]
7. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2005 Oct; 54(40):1023-5. PubMed ID: 16224452 [TBL] [Abstract][Full Text] [Related]
9. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach. Cho BH; Clark TA; Messonnier NE; Ortega-Sanchez IR; Weintraub E; Messonnier ML Vaccine; 2010 Jan; 28(3):817-22. PubMed ID: 19879992 [TBL] [Abstract][Full Text] [Related]
10. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Velentgas P; Bohn RL; Brown JS; Chan KA; Gladowski P; Holick CN; Kramer JM; Nakasato C; Spettell CM; Walker AM; Zhang F; Platt R Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1226-34. PubMed ID: 18956428 [TBL] [Abstract][Full Text] [Related]
11. Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine. Ann Pharmacother; 2006 May; 40(5):1007. PubMed ID: 16670362 [No Abstract] [Full Text] [Related]
12. Alert on meningococcal vaccine. FDA Consum; 2005; 39(6):6. PubMed ID: 16669110 [No Abstract] [Full Text] [Related]
13. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. De Wals P; Deceuninck G; De Serres G; Boivin JF; Duval B; Remis R; Massé R Clin Infect Dis; 2005 Apr; 40(8):1116-22. PubMed ID: 15791510 [TBL] [Abstract][Full Text] [Related]
14. Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5-14 years old children. Esteghamati A; Gouya MM; Keshtkar AA; Mahoney F Vaccine; 2008 Sep; 26(39):5058-61. PubMed ID: 18662736 [TBL] [Abstract][Full Text] [Related]
15. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R; Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096 [TBL] [Abstract][Full Text] [Related]
16. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM; Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428 [TBL] [Abstract][Full Text] [Related]
17. Recurrent Guillain-Barre syndrome following vaccination. Baxter R; Lewis N; Bakshi N; Vellozzi C; Klein NP; Clin Infect Dis; 2012 Mar; 54(6):800-4. PubMed ID: 22267712 [TBL] [Abstract][Full Text] [Related]
18. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005). Souayah N; Nasar A; Suri MF; Qureshi AI J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097 [TBL] [Abstract][Full Text] [Related]